Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

8.040 +0.200 (+2.55%)
Streaming Delayed Price Updated: 1:50 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 481,986
Open 7.765
Bid (Size) 8.030 (200)
Ask (Size) 8.050 (700)
Prev. Close 7.840
Today's Range 7.765 - 8.141
52wk Range 7.230 - 14.93
Shares Outstanding 54,532,614
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-1.6%
-1.6%
1 Month
-16.5%
-16.5%
3 Month
-40.5%
-40.5%
6 Month
-26.8%
-26.8%
1 Year
-4.3%
-4.3%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
From Pomerantz LLP
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-04-01: top gainers and losers in today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
News headline image
What's Behind The Drop In Oric Pharmaceuticals Stock Today? ↗
Via Benzinga
These stocks are gapping in today's session ↗
Via Chartmill
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
Topics Stocks
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Oric Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Oric Pharmaceuticals, Inc. - Common Stock trade on?
Oric Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock is ORIC on the Nasdaq Stock Market
What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?
The current price of Oric Pharmaceuticals, Inc. - Common Stock is 8.040
When was Oric Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 06/04/26 01:50 PM ET
What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 438.44M
How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?
Oric Pharmaceuticals, Inc. - Common Stock has 438M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.